Newly published preclinical research signals a substantial conceptual shift with a potential role of photon-counting CT in targeting specific biological processes.
|Articles|November 20, 1996
Medical Resources to buy two centers
Imaging services firm Medical Resources has signed an agreementto buy two imaging centers in New York, a deal that will add tothe Hackensack, NJ, company's concentration of 14 imaging facilitiesin the New York/New Jersey market. The transaction, which is
Advertisement
Imaging services firm Medical Resources has signed an agreement
to buy two imaging centers in New York, a deal that will add to
the Hackensack, NJ, company's concentration of 14 imaging facilities
in the New York/New Jersey market. The transaction, which is expected
to close this month, will bring to 38 the total number of centers
owned by the company.
Advertisement
Related to this article
The future of AI in radiology lies in its potential capability to forge connections and enhance efficiencies for enterprise-wide workflows.
In a new podcast episode, Joseph Cavallo, MD, MBA, offered his perspective on AI integration, potential efficiency gains, navigating post-deployment monitoring and how to incorporate AI literacy into radiology resident training.
The FFR-IQ software recently demonstrated a 92.2 percent sensitivity for non-invasive estimation of fractional flow reserve (FFRC) based on coronary CT angiography (CCTA) scans.
A Kaiser score > 5 with breast MRI demonstrated a 97 percent sensitivity and 87.9 percent specificity for predicting malignancy in patients with BI-RADS 0 or 4 presentations on mammography and breast ultrasound, according to a new study.
In a recent interview, Francesco Giganti, MD, PhD, discussed findings from a recent multicenter study demonstrating the ability of an AI software to provide significant clarity to initial PI-RADS 3 assessments on MRI and facilitate a nearly 19 percent reduction in unnecessary prostate biopsies.
The NEXT-Cue AI software, which incorporates analysis of brain MRI scans, reportedly facilitates prognostic assessments of potential progression from mild cognitive impairment (MCI) to Alzheimer’s disease within five years.
In a new podcast episode, Amir Iravani, MD, FRACP, discusses emerging dosimetry data from the COMPETE trial for 177Lu-edotreotide and how it may help facilitate more personalized treatment for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears MRI-Based AI Software for Prognostic Evaluation of Patients with Mild Cognitive Impairment
2
FDA Clears AI-Enabled FFR-IQ Software for Estimating Fractional Flow Reserve from CCTA
3
How AI, Theranostics and More Empowered Patients Have Led to Significant Changes in Radiology
4
What’s Next for AI in Radiology?: Facilitating Data Orchestration Over Fragmentation
5